Goldman Sachs has made a significant move by downgrading Dynavax Technologies Corporation (NASDAQ: DVAX), citing revised perspectives and evolving competitive landscapes in the realm of vaccines. As per the insights of Goldman Sachs analyst Paul Choi, Dynavax has been downgraded from a Neutral rating to a Sell rating, along with a reduction in the price target from $15 to $12. The rationale behind this decision is the increasing competition observed in the shingles vaccine market. This heightened competition could potentially diminish the value proposition of Dynavax’s Z-1018 program and introduce uncertainties regarding its future revenue streams.
An interesting development in the vaccine market comes from GSK Plc (NYSE: GSK) and its product Shingrix, which offers potential convenience enhancements through pre-filled syringes. Noteworthy is that GSK’s Shingrix has garnered regulatory acceptance for review from both the FDA and EMA, with a decision expected from the U.S. by June 20th. In response to emerging competitive dynamics, Dynavax is currently in the process of conducting a Phase 1/2 trial to assess the safety, tolerability, and immunogenicity of Z-1018 in comparison to GSK’s Shingrix, targeting 441 healthy adults aged 50 to 69.
Furthermore, Choi highlights the uncertain demand projections for repeat hepatitis B vaccinations in the 2030s, which could potentially impact the future prospects of Dynavax’s Heplisav-B beyond its peak sales trajectory. Despite the company’s market share gains, concerns linger regarding the regulatory stance of the FDA and ACIP toward vaccines in the United States.
In its recent financial disclosures, Dynavax reported preliminary HEPLISAV-B net product revenue of $268 million for the year 2024, marking a 26% year-over-year increase. The net product revenue for HEPLISAV-B in the fourth quarter of 2024 reached $71 million, reflecting a significant 39% growth. However, the company faced a setback in May 2024 when the FDA issued a Complete Response Letter, indicating that the application lacked sufficient data to thoroughly evaluate the efficacy and safety of a four-dose regimen of HEPLISAV-B.
Looking ahead, Dynavax is scheduled to announce its fourth-quarter earnings on February 20th. Analysts, as per data from Benzinga Pro, anticipate an adjusted EPS of $0.04 for Q4, with sales estimated at $72.92 million. Projections for 2024 sales stand at $278.13 million, with an adjusted EPS forecast of $0.12.
At the time of last update, DVAX stock was down by 4.13%, trading at $12.66 on Tuesday. Investors and analysts are closely monitoring the developments surrounding Dynavax amid the shifting landscape of the biopharmaceutical industry.
For more insights and analysis on DV
